Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

Por Wong, Andrea L. A., Lee, Soo-Chin
Publicado em 2012

Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients

Por Voon, Pei Jye, Yap, Hui Ling, Ma, Cho-Yee-Thu, Lu, Fan, Wong, Andrea L A, Sapari, Nur Sabrina, Soong, Richie, Soh, Thomas I P, Goh, Boon-Cher, Lee, How-Sung, Lee, Soo-Chin
Publicado em 2013

Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer

Por Wong, Andrea L.A., Sundar, Raghav, Wang, Ting-Ting, Ng, Thian-C, Zhang, Bo, Tan, Sing-Huang, Soh, Thomas I.P., Pang, Angela S.L., Tan, Chee-Seng, Ow, Samuel G.W., Wang, Lingzhi, Mogro, Jannet, Ho, Jingshan, Jeyasekharan, Anand D., Huang, Yiqing, Thng, Choon-Hua, Chan, Ching-Wan, Hartman, Mikael, Iau, Philip, Buhari, Shaik A., Goh, Boon-Cher, Lee, Soo-Chin
Publicado no Oncotarget (2016)